Jump directly to the content
RAYS OF HOPE

Single-dose Janssen Covid vaccine could be approved ‘in weeks’ to help protect millions

A THIRD Covid jab could be given the green light within weeks, helping to accelerate the mass vaccination programme.

The Government has ordered 30million doses of the single-dose Janssen vaccine - developed by pharma giants Johnson & Johnson.

⚠️ Read our coronavirus live blog for the latest news & updates

The MHRA wants to cut Covid vaccine batch testing from 20 days to around four or five
8
The MHRA wants to cut Covid vaccine batch testing from 20 days to around four or fiveCredit: PA:Press Association
Approval of Covid vaccine batches will be cut from 20 days to just four or five
8
Approval of Covid vaccine batches will be cut from 20 days to just four or fiveCredit: PA:Press Association

It comes as testing of current Covid vaccine batches is set to be accelerated from 20 days to just five to get jabs out more quickly across the UK.

The Medicines and Healthcare Regulatory Agency, which is responsible for the checks, is also to increase staffing in a bid to accelerate the mass vaccination programme, reports the .

Faster rollout of the jab campaign is needed to speed up the end to lockdown by vaccinating more than 13m of the most vulnerable Brits by mid-February.

Up to now the MHRA’s National Institute for Biological Standards and Control has only checked batches one by one at its site in Hertfordshire.

But the process has been changed so more than one batch can be assessed at a time, cutting the timescale from up to 20 days to around five.

Vaccines available to the UK

THE UK government has placed orders for seven different vaccines - totalling more than 300 million jabs

  • AstraZeneca/Oxford university - 100 million doses - Approved
  • Pfizer/BioNTech - 40 million doses - Approved
  • Janssen - 30 million doses - Phase 3 trials
  • Moderna - 5 million doses - Phase 3 trials
  • Novavax - 60 million doses - Phase 3 trials
  • Valneva - 60 million doses - Phase 1/2 trials
  • GSK/Sanofi - 60 million doses - Phase 1/2 trials

“We are working closely with the manufacturer, AstraZeneca, to ensure batches of the vaccine are released as quickly as possible,” said an MHRA spokesman.

“Biological medicines such as vaccines are very complex in nature and independent testing, as done by the National Institute, is vital to ensure quality and safety.

“The institute has scaled up its capacity to ensure that multiple batches can be tested simultaneously, and that this can be done as quickly as possible, without compromising quality and safety.”

Despite plans for a quicker turnaround of vaccine batch approvals, both the Pfizer and the Oxford doses need to be given as two separate doses, some weeks apart.

Brian Pinker, 82, was among the first to get the Oxford AstraZeneca vaccine on Monday
8
Brian Pinker, 82, was among the first to get the Oxford AstraZeneca vaccine on MondayCredit: Reuters
Health workers have been vaccinating patients with the Oxford vaccine this week
8
Health workers have been vaccinating patients with the Oxford vaccine this weekCredit: Pacific Coast News

But there are plans for the launch of a new single-dose vaccine, that could mark a huge acceleration in giving more Brits immunity from Covid-19.

Ministers hope the Janssen jab, using similar technology to the Oxford vaccine, could be granted emergency authorisation within weeks, reports .

The UK has already ordered 30 million doses of the Janssen vaccine, with the option of 22 million more.

If approved by regulators, the Janssen drug would become the third vaccine to be rolled out at scale in the UK after the Pfizer and AstraZeneca jabs.

It can be stored at standard fridge temperature and trials have so far focused on its effectiveness when used as a single dose, which marks a big change from the double-dose vaccines currently available.

The new vaccine could help the Government hit its target of vaccinating the four most vulnerable groups by mid-February, say experts.

Chief Medical Officer Chris Whitty this week revealed that one in every 50 Brits now has coronavirus, while hospital admissions are 40 per cent higher than at the peak of the first wave in April 2020.

Sir John Bell, regius professor at Oxford University and an adviser to the UK's Vaccine Taskforce, said the drug was "highly likely to work".

"My prediction is that it'll work well, although we need to wait for the trial results," he told The Telegraph. "I think they will have supplies available for the UK in a time frame that would allow it just to catch the mid-February target of getting the numbers up.

"I think it may well have a material impact on what we can do in the UK to get more people vaccinated."

Developed by Janssen, the Belgium-based pharmaceutical arm of Johnson & Johnson, the vaccine uses a modified adenovirus like the Oxford vaccine, rather than the mNRA technology used by the Pfizer jab.

Scientists launched trials of the drug on around 30,000 people worldwide in November, including 6,000 across 17 sites in the UK, to check how effective it is when spaced out in two doses as well as just one dose.

The vaccine is currently going through final data examination and should be filing for approval from US, European and UK regulators in early February.

If that is successful, Johnson & Johnson has said it is ready get vaccines out from its European factories straight away.

We are really hopeful of good results from the single dose trial

Professor Saul Faustdirector of the NIHR Southampton Clinical Research Facility

Professor Saul Faust, director of the NIHR Southampton Clinical Research Facility and the chief investigator leading the trial, said: “We are really hopeful of good results from the single dose trial.

"Johnson & Johnson are a large drug company, experienced at making vaccines, who know how to make and transport vaccines at pace and scale, if it works.”

He added: “We need all the vaccines, and it might well be that one dose will be approved by the regulators for emergency use.

“But we don't know yet. And we won't know until the trials are done.”

The news comes as deaths top 1,000 for first time since April and cases hit the highest ever for second day in a row.

 

Prime Minister Boris Johnson watched vaccinations at Chase Farm Hospital in north London this week
8
Prime Minister Boris Johnson watched vaccinations at Chase Farm Hospital in north London this weekCredit: No 10 Downing Street / BEEM
Boris Johnson wants to rollout vaccinations to all four priority groups by mid February
8
Boris Johnson wants to rollout vaccinations to all four priority groups by mid FebruaryCredit: No 10 Downing Street / BEEM
Epsom Racecourse is one of the new vaccination centres
8
Epsom Racecourse is one of the new vaccination centres Credit: PA:Press Association
Rollout of the Oxford jab began on Monday
8
Rollout of the Oxford jab began on MondayCredit: AFP or licensors

Deaths today rose by 1,041 - bringing the total to 77,346 - in the highest rise since April 21 when 1,224 were recorded by the government.

But media outlets have reported the deadliest ever day was April 8 when 1,445 sadly died after deaths hit 1,000 for 22 days in a row.

The total number of cases now stands at 2,836,801 after 62,322 more infections were recorded.

NHS England chief executive Sir Simon Stevens is expected to appear at a Downing Street press briefing to unveil plans including 1,000 vaccination centres operating in hospitals and GPs by the end of the week.

The plan also includes seven huge vaccination centres opening next week in London, Newcastle, Manchester, Birmingham, Bristol, Surrey and Hertfordshire.

READ MORE SUN STORIES

Superdrug is expected to be used as part of the NHS vaccination effort, while drive-through jabs will take place in the car parks of Morrisons stores from Monday.

Doctors being told to prioritise jabs over other treatments, according to latest reports.

Coronavirus deaths top 1,000 for first time since April and cases are highest ever for second day running with 62,322
Topics